{"title":"Response to the letter to the editor: \"pediatric bowel-wall thickness cutoffs: calibration before implementation\".","authors":"Laura Räisänen","doi":"10.1093/ibd/izag132","DOIUrl":"10.1093/ibd/izag132","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2080-2081"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148345052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yushan Pan, Katie A Dunleavy, Ashwin N Ananthakrishnan
{"title":"Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis.","authors":"Yushan Pan, Katie A Dunleavy, Ashwin N Ananthakrishnan","doi":"10.1093/ibd/izag086","DOIUrl":"10.1093/ibd/izag086","url":null,"abstract":"<p><strong>Background: </strong>A quarter of patients with ulcerative colitis who undergo total proctocolectomy with ileal pouch-anal anastomosis experience chronic pouchitis. While advanced therapies (ATs) are effective in some patients, their impact on antibiotic dependence is unclear.</p><p><strong>Methods: </strong>In a multicenter, retrospective study, we identified adults with chronic pouchitis during treatment with AT. Those with complete pre-AT antibiotic data formed the \"incident AT user\" cohort. Those with only post-AT data formed the \"prevalent AT user\" cohort. Antibiotic prescription was modeled as percentage of time, calculated as the number of weeks of antibiotic prescription during the weeks of observed time. The pooled prevalence of antibiotic use during AT was calculated in a systematic review and meta-analysis,.</p><p><strong>Results: </strong>Of the 67 incident AT users, 24 (36%) initiated treatment with tumor necrosis factor-α antagonist, 17 (25%) with anti-integrin, 23 (34%), with interleukin (IL) inhibitors (anti-IL), and 3 (5%) with Janus kinase inhibitors. The mean time on antibiotics was unchanged from 38% to 33% after AT initiation, and 61% of patients (n = 44) had a reduction in antibiotic use. Compared to the patients without reduction, the reduction group had a higher proportion of patients on anti-IL (46% vs 15%, adjusted odds ratio [OR] 11.1; 95% CI, 2.12-57.62). There were no differences in disease-related parameters. Seventy-nine percent (22/28) of prevalent AT users required antibiotics. On meta-analysis, pooled prevalence of antibiotic use was 0.46 (95% CI, 0.35-0.57).</p><p><strong>Conclusions: </strong>Just over half of patients on AT for chronic pouchitis saw reduced antibiotic use; however, further studies are needed to identify impact of AT on antibiotic use and define which patients benefit from immune-mediated vs microbiome-directed therapy.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1910-1918"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626224/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ricardo G Suarez, Ori Bar Or, Esther Orlanski-Meyer, Zivia Shavit, Asaf Azulay, Efrat Broide, Darja Urlep, Art Kastl, Jeffrey S Hyams, Jeremiah Levine, Joel Rosh, Richard K Russell, Dan Turner, Eytan Wine
{"title":"Metabolomics predict treatment response to vedolizumab in pediatric IBD: results from the prospective VedoKids cohort study.","authors":"Ricardo G Suarez, Ori Bar Or, Esther Orlanski-Meyer, Zivia Shavit, Asaf Azulay, Efrat Broide, Darja Urlep, Art Kastl, Jeffrey S Hyams, Jeremiah Levine, Joel Rosh, Richard K Russell, Dan Turner, Eytan Wine","doi":"10.1093/ibd/izag154","DOIUrl":"10.1093/ibd/izag154","url":null,"abstract":"<p><strong>Background and aim: </strong>Metabolites produced through host-microbe interactions may help associate metabolomic signatures with therapy response. We aimed to assess serum metabolites as predictors of vedolizumab remission in children with IBD.</p><p><strong>Methods: </strong>VedoKids was a multicenter, prospective cohort study of children initiating vedolizumab at any stage of disease. Serum metabolomic profiling was performed at baseline (W0), week 14 (W14), and week 30 (W30) using quantitative metabolomics based on DI/LC-MS/MS method. Random Forest (RF) models with maximum relevance-minimum redundancy (mRMR) feature selection, integrated clinical and metabolomic features to predict clinical remission at the next time point (ie, week 0 to week 14; week 14 to week 30; week 30 to week 54).</p><p><strong>Results: </strong>One hundred thirty-eight patients were included (mean age 13.6 years), 64 with Crohn disease (CD) and 74 with ulcerative colitis (UC). In CD, models achieved an area under the receiver operating characteristic curve (AUROC) of 0.80 (95% CI, 0.68-0.92) for predicting response to vedolizumab at W14, 0.92 (95% CI, 0.85-0.99) at W30 , and 0.83 (95% CI, 0.72-0.94) at W54. Metabolites appeared among the most important features, notably PC ae C36:4, citric acid, and malic acid. In UC, corresponding AUROC were 0.72 (95% CI, 0.59-0.85) at W14, 0.77 (95% CI, 0.64-0.90) at W30, and 0.90 (95% CI, 0.80-1.00) at W54. LysoPC a C26:1, picolinic acid, and serotonin were among the most important metabolites for prediction.</p><p><strong>Conclusions: </strong>We identified serum metabolites associated with vedolizumab remission in children with IBD, several of which have been previously linked to IBD pathophysiology.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1880-1887"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Comparative efficiency of leucine-rich alpha-2 glycoprotein and fecal calprotectin to assess endoscopic activity in Crohn's disease: a prospective observational study.","authors":"Tatsuya Kawamura, Takeshi Yamamura, Masanao Nakamura, Keiko Maeda, Tsunaki Sawada, Eri Ishikawa, Kentaro Murate, Takashi Hirose, Takuya Ishikawa, Kazuhiro Furukawa, Takashi Honda, Muneyori Okita, Hiroki Kawashima","doi":"10.1093/ibd/izag105","DOIUrl":"10.1093/ibd/izag105","url":null,"abstract":"<p><strong>Background: </strong>Endoscopic healing is a key therapeutic target for Crohn's disease (CD). However, endoscopy is invasive, and simple, non-invasive biomarkers are needed to assess endoscopic healing. Although leucine-rich alpha-2 glycoprotein (LRG) and fecal calprotectin (FC) are indicators of inflammatory bowel disease activity, few studies have directly compared them for endoscopic disease activity in CD. We aimed to compare the ability of these markers to assess endoscopic remission in CD.</p><p><strong>Methods: </strong>From October 2022 to December 2023, 100 patients with CD at Nagoya University Hospital were prospectively and consecutively enrolled. Endoscopic activity was assessed using the applied simple endoscopic score for Crohn's disease (aSES-CD), incorporating small bowel lesions. The primary endpoint was the sensitivity of LRG and FC in endoscopic remission (aSES-CD ≤ 3), which was tested using McNemar's exact test. Logistic regression analysis was used to identify factors associated with endoscopic remission.</p><p><strong>Results: </strong>Overall, 84 patients were analyzed (79.8% male; median age 49.5 years). The receiver operating characteristic curve analysis yielded sensitivity/specificity values of 85.9%/90.0% for LRG and 70.3%/85.0% for FC, using cutoff values of 11 µg/mL (LRG) and 100 µg/g (FC) for endoscopic remission. Based on these values, a comparison of sensitivities between LRG and FC showed that LRG had significantly higher sensitivity (P = .013). In multivariate analysis, only LRG was an independent factor for endoscopic remission (odds ratio 3.016; 95% CI, 1.506-6.037).</p><p><strong>Conclusions: </strong>Compared with FC, LRG shows a higher sensitivity for assessing endoscopic remission. LRG may serve as a useful biomarker for endoscopic activity in CD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1969-1979"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148258119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis.","authors":"Karan Sachdeva, Dhruv Manik, Tarun Chhibba, Ashwin Ananthakrishnan","doi":"10.1093/ibd/izag075","DOIUrl":"10.1093/ibd/izag075","url":null,"abstract":"<p><strong>Background and aims: </strong>Extraintestinal manifestations (EIMs) occur in one-fifth of patients with inflammatory bowel diseases (IBDs) (Crohn's disease[CD]; ulcerative colitis [UC]). As advanced therapies (ATs) for IBD become more targeted, effectiveness for luminal disease may not be extrapolatable to EIMs. We conducted a systematic review to evaluate the efficacy of ATs on EIMs in IBD.</p><p><strong>Methods: </strong>We conducted searches in PubMed/Embase (inception March 2025) for studies of any of the 5 FDA approved AT classes (tumor necrosis factor [TNF] antagonists, Janus kinase [JAK] inhibitors, anti-integrins, anti-interleukins [anti-ILs], and S1P receptor modulators) for musculoskeletal (arthritis, arthralgias), dermatologic (erythema nodosum, pyoderma gangrenosum), or ocular EIMs in patients with IBD. The primary outcome was clinical improvement. The pooled improvement rates by EIM type and AT class were calculated using a random effects model to account for anticipated heterogeneity.</p><p><strong>Results: </strong>A total of 49 studies were included in the final analysis (6 randomized clinical trials [RCTs], 1 pooled analysis of clinical trials, and 42 observational studies). For musculoskeletal EIMs, TNF antagonists achieved response in 61% of patients, with higher response rates for peripheral (73%) than axial (57%) arthritis. JAK inhibitors were similarly effective (65%) while vedolizumab had significantly lower efficacy (42% improvement), particularly for axial arthritis (12%). For dermatologic EIMs, systemically directed ATs had high efficacy (TNF antagonists 89%, anti-IL 91%). There was a paucity of data on ocular EIMs.</p><p><strong>Conclusion: </strong>Systemically directed ATs (TNF-antagonists, JAK inhibitors, anti-ILs) demonstrated strong efficacy for musculoskeletal or cutaneous EIMs; vedolizumab achieved clinical response in lower rates, particularly for axial arthritis.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2050-2060"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147868169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"TL1A and DR3 in IBD: from mucosal immunopathology to a new era of targeted therapy.","authors":"Randy S Longman","doi":"10.1093/ibd/izag116","DOIUrl":"10.1093/ibd/izag116","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"2072-2074"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148271486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Eun Soo Kim, Dong Hyun Kim, Seong-Jung Kim, Sang Hyoung Park, Hyun Seok Lee, Sung Kook Kim, Hyun Soo Kim, Jun Lee, Kyeong Ok Kim, Byung Ik Jang, Yoo Jin Lee, Eun Mi Song, Dae Sung Kim, Chun-Chi Lin, Joyce Wing Yan Mak, Jing Liu, Qian Cao, Shu-Chen Wei, Wei-Chen Lin, Wen-Hung Hsu, Shintaro Sagami, Taku Kobayashi, Richard G Fernandes, Robert Gilmore, Yoon-Kyo An, Jakob Begun, Katie Rice, Leonie Ruddick-Collins, Abhinav Vasudevan, Jennifer Zhang, Anthony Brownson, Benjamin Ngoi, Kate Lynch, Craig Haifer, Lucy Mary Lilian Bracken, Ei Swe, Emily Wright, Nicholas Clark, Tamar Schildkraut, Gillian Mahy, Gregory Moore, Kathryn Gazelakis, Mayur Garg, Michael Schultz
{"title":"Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations.","authors":"Eun Soo Kim, Dong Hyun Kim, Seong-Jung Kim, Sang Hyoung Park, Hyun Seok Lee, Sung Kook Kim, Hyun Soo Kim, Jun Lee, Kyeong Ok Kim, Byung Ik Jang, Yoo Jin Lee, Eun Mi Song, Dae Sung Kim, Chun-Chi Lin, Joyce Wing Yan Mak, Jing Liu, Qian Cao, Shu-Chen Wei, Wei-Chen Lin, Wen-Hung Hsu, Shintaro Sagami, Taku Kobayashi, Richard G Fernandes, Robert Gilmore, Yoon-Kyo An, Jakob Begun, Katie Rice, Leonie Ruddick-Collins, Abhinav Vasudevan, Jennifer Zhang, Anthony Brownson, Benjamin Ngoi, Kate Lynch, Craig Haifer, Lucy Mary Lilian Bracken, Ei Swe, Emily Wright, Nicholas Clark, Tamar Schildkraut, Gillian Mahy, Gregory Moore, Kathryn Gazelakis, Mayur Garg, Michael Schultz","doi":"10.1093/ibd/izag098","DOIUrl":"10.1093/ibd/izag098","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to develop predictive models for acute severe ulcerative colitis (ASUC) using data from East Asian (EA) patients and to validate their performance in an Australia/New Zealand (ANZ) cohort.</p><p><strong>Methods: </strong>A retrospective international study was conducted across 23 referral hospitals in EA and ANZ, enrolling consecutive ASUC patients between January 2015 and December 2022. Logistic regression analyses were used to construct predictive models for 1-year colectomy and non-response to corticosteroid therapy (NRS).</p><p><strong>Results: </strong>Overall, 826 patients with ASUC were included (411 EA and 415 ANZ). Among EA patients, independent predictors of 1-year colectomy included female sex, prior exposure to tumor necrosis factor inhibitors, and admission albumin ≤3 g/dL. Independent predictors of NRS in the EA cohort were age at diagnosis ≤37 years, baseline steroid use, admission albumin ≤2.5 g/dL, and the presence of extraintestinal manifestations. The EA-derived scoring systems demonstrated strong predictive performance within the EA cohort (1-year colectomy: P < .0001; NRS: P = .001) but showed limited utility in the ANZ cohort (P = .106 and P = .012). In contrast, European-developed models-including the French 1-year colectomy score and the ADMIT-ASC index for NRS-accurately predicted outcomes in the ANZ cohort (P = .007 and P < .0001) but had reduced predictive capacity in the EA cohort (P = .106 and P = .026). These findings were consistent in both cohorts following propensity score matching.</p><p><strong>Conclusions: </strong>Predictive factors for ASUC differ substantially between EA and ANZ patients, highlighting the need for population-specific predictive tools.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1957-1968"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148162783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peter F G Foulser, Laura Martinez-Gili, Sharmili Balarajah, Rohan Sundramoorthi, James L Alexander, Benjamin H Mullish, Julian R Marchesi, Miles Parkes, Timothy R Orchard, Lucy C Hicks, Horace R T Williams
{"title":"Disease phenotype affects treatment of late-onset inflammatory bowel disease: Analysis of a large UK cohort.","authors":"Peter F G Foulser, Laura Martinez-Gili, Sharmili Balarajah, Rohan Sundramoorthi, James L Alexander, Benjamin H Mullish, Julian R Marchesi, Miles Parkes, Timothy R Orchard, Lucy C Hicks, Horace R T Williams","doi":"10.1093/ibd/izag072","DOIUrl":"10.1093/ibd/izag072","url":null,"abstract":"<p><strong>Background: </strong>The incidence of inflammatory bowel disease (IBD) in older adults is rising. Studies of late-onset (LO) (diagnosis ≥60 years of age) IBD are contradictory, with some suggesting increased use of corticosteroid and reduced use of advanced therapies. This multicenter study assessed disease phenotype and therapeutic choice in LO-IBD.</p><p><strong>Methods: </strong>Patients recruited to the NIHR IBD BioResource with LO ulcerative colitis (UC) or Crohn's disease (CD) were compared with those with young-onset (YO) (16-39 years of age) and mid-onset (MO) (40-59 years of age) IBD. Medication use and surgeries were assessed in propensity score-matched cohorts.</p><p><strong>Results: </strong>A total of 32 012 patients were studied: 16 930 UC (2247 LO) and 15 082 CD (1409 LO). LO-UC was mostly left-sided, with less isolated proctitis. LO-CD patients had less ileocolonic and perianal disease. Corticosteroid, immunomodulator, and anti-tumor necrosis factor α (anti-TNF) use was lower in LO-UC and LO-CD; however, there was no difference in time to colectomy (LO-UC) or intestinal resection (LO-CD) compared with younger patients. LO-CD patients were more likely to receive vedolizumab and ustekinumab than YO-CD (odds ratio, 0.34 [95% confidence interval, 0.18-0.61] and 0.29 [95% confidence interval, 0.09-0.76], respectively). LO patients with perianal CD were less likely to receive anti-tumor necrosis factor or undergo perianal surgery than YO and MO patients with perianal CD (all P < .01).</p><p><strong>Conclusions: </strong>LO-IBD has a distinct phenotype, with less isolated proctitis (LO-UC) and less ileocolonic and perianal CD. LO-IBD patients had lower corticosteroid, immunomodulator, and anti-tumor necrosis factor use but equivalent colectomy and intestinal resection rates. LO-CD is notable for the higher use of vedolizumab and ustekinumab, suggesting that age, comorbidity, and disease phenotype affect biologic choice in older adults. Research to understand whether differential treatment of older adults is justified is crucial.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1888-1897"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13626234/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147837414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Giovanni Maconi, Cristina Bezzio, Adam Saleh, Sofia Silva Mendes, Federica Lepore, Bincy P Abraham, Dan Carter
{"title":"Transperineal contrast-enhanced ultrasound: a rapid and reliable tool for differentiating abscesses from inflammatory masses in perianal Crohn's disease.","authors":"Giovanni Maconi, Cristina Bezzio, Adam Saleh, Sofia Silva Mendes, Federica Lepore, Bincy P Abraham, Dan Carter","doi":"10.1093/ibd/izag089","DOIUrl":"10.1093/ibd/izag089","url":null,"abstract":"<p><strong>Background and aim: </strong>Perianal abscesses are serious complications of Crohn's disease (CD) requiring timely and accurate diagnosis. Contrast-enhanced ultrasound (CEUS), which in abdominal intestinal ultrasound (IUS) has shown diagnostic performance comparable to CT/MRI in distinguishing intra-abdominal abscesses from inflammatory masses, has not been systematically evaluated in the transperineal assessment of perianal Crohn's disease. This study aimed to evaluate the diagnostic performance, inter- and intra-observer agreement, and diagnostic confidence of transperineal CEUS versus conventional B-mode TPUS in CD patients with perianal symptoms and suspected septic complications.</p><p><strong>Methods: </strong>We retrospectively reviewed 52 examinations of 37 adult CD patients presenting with painful perianal symptoms and suspected septic complications. Patients were included if TPUS detected lesions > 10 mm requiring CEUS characterization. Exclusion criteria were CEUS contraindications, simple fistulas, or large (>3 cm) obvious abscesses. All examinations were recorded, and three blinded experts independently assessed anonymized videos in random order. Lesions were classified as abscesses, inflammatory masses, or phlegmons. Agreement for lesion size, fluid content, and final diagnosis was evaluated using intraclass correlation coefficients (ICC) and Fleiss-Cohen's kappa (κ). Diagnostic confidence was assessed using a 5-point Likert scale.</p><p><strong>Results: </strong>On B-mode, 17 abscesses, 32 inflammatory masses, and 3 phlegmons were identified. CEUS reclassified several, yielding 16 abscesses, 31 inflammatory masses, and 5 phlegmons. Of the 17 abscesses diagnosed on B-mode, only 4 were also classified as abscesses on CEUS, while 13 were reclassified; conversely, 11 inflammatory masses were reclassified as abscesses. Intra-observer reliability improved from κ = 0.55 with B-mode to κ = 0.95 with CEUS. Inter-observer agreement for diagnosis was poor with B-mode (κ = 0.31) but excellent with CEUS (κ = 0.83).</p><p><strong>Conclusions: </strong>Transperineal CEUS significantly improves inter- and intra-observer agreement and diagnostic confidence compared with conventional B-mode TPUS when differentiating perianal abscesses from inflammatory masses/phlegmons in CD and frequently leads to lesion reclassification in clinically ambiguous cases.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1928-1936"},"PeriodicalIF":5.5,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148029858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}